AVA: Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
Study Details
Study Description
Brief Summary
To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Persistent thrombocytopenia is a common complication after umbilical cord blood transplantation (UCBT), which necessitates platelet transfusion and leads to increased transplant-related mortality. This is a single-center, single-arm, phase II clinical trial aimed at evaluating the efficacy and safety of Avatrombopag for platelet recovery after UCBT in patients with bone marrow failure disease (BMFD). The study was conducted in patients diagnosed with BFMD and receiving UCBT. After the subjects signed and informed and qualified, they received Avatrombopag treatment from the first day to the 28th day after transplantation. In this study, the cumulative of platelet implantation rate at 28 days after transplantation was used as the main therapeutic index, and 40 patients were planned to be enrolled.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Avatrombopag group The duration of the study is 4 weeks, from +1 day to +28 days after UCBT, patients will be given Avatrombopag with a recommended dose of 40mg per day. After 28 days of administration, the patients may continue, change or discontinue medication based on the patients' platelet status. |
Drug: Avatrombopag
Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10^9/L; Drug administration will be stopped when PLT≥100×10^9/L.
|
Outcome Measures
Primary Outcome Measures
- Time of platelet engraftment [28 days]
Platelet engraftment is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥20 × 10^9/L.
- The cumulative incidence of platelet engraftment at 28 days after transplantation [28 days]
Platelet engraftment is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥20 × 10^9/L.
Secondary Outcome Measures
- The cumulative incidence of platelet recovery rate at 28 days after transplantation [28 days]
Platelet recovery was defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥50×10^9/L.
- Total platelet transfusion during 4 weeks of treatment [28 days]
Total platelet transfusion during 4 weeks of treatment
- neutrophil reconstitution [28 days]
neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10^9/L.
- erythroid reconstitution [28 days]
RBC engraftment time was defined as the first day of achieving a reticulocyte count greater than 1% for 3 consecutive days.
- Megakaryocyte levels in bone marrow smears 4 weeks after treatment [4 weeks]
Megakaryocyte levels in bone marrow smears 4 weeks after treatment
- Time of platelet recovery [100 days]
Platelet count ≥50×10^9/L for 3 consecutive days without platelet transfusions for 7 consecutive days
- Time of platelet ≥100×10^9/L. [100 days]
Platelet count ≥100×10^9/L for 3 consecutive days without platelet transfusions for 7 consecutive days
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥12 years old, male or female;
-
Patients diagnosed with bone marrow failure disease including aplastic anemia (AA), Fanconi anemia (FA), paroxysmal nocturnal hemoglobinuria (PNH) and undergoing UCBT;
-
ECOG score ≤2;
-
Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent；
Exclusion Criteria:
-
Pregnant or lactating women；
-
Known allergy to Avatrombopag;
-
A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation;
-
A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;
-
Chronic active hepatitis B and C;
-
Repeat or multiple transplantation or multiple organ transplantation;
-
HIV positive, EBV-DNA positive, CMV-DNA positive;
-
Have severe infection or complicated with serious heart, liver, lung, kidney, neurological or metabolic diseases;
-
A serious adverse event (Level 4 or 5) as defined by the Standard General Terminology for Adverse Events Version 4.0 occurred during the pre-treatment period;
-
Participants participate in another clinical study with any exploratory drug or device within 30 days prior to baseline visit; Observational studies are allowed;
-
Subjects with cognitive impairment or uncontrolled mental illness;
-
Subjects and/or authorized family members to refuse treatment with Avatrombopag;
-
Those who are judged by the researchers as not suitable for inclusion (such as accompanying medical history, which may affect the safety of the subjects or it is estimated that the treatment cannot be adhered to due to financial problems).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) | Hefei | Anhui | China | 230036 |
Sponsors and Collaborators
- Anhui Provincial Hospital
Investigators
- Principal Investigator: Xiaoyu Zhu, ph.D, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AVA&MDS-001